These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 34196885)

  • 1. Correction to: NIX protein enhances antioxidant capacity of and reduces the apoptosis induced by HSP90 inhibitor luminespib/NVP-AUY922 in PC12 cells.
    Zhang H; Ge F; Shui X; Xiang Y; Wang X; Liao C; Wang J
    Cell Stress Chaperones; 2021 Jul; 26(4):741. PubMed ID: 34196885
    [No Abstract]   [Full Text] [Related]  

  • 2. NIX protein enhances antioxidant capacity of and reduces the apoptosis induced by HSP90 inhibitor luminespib/NVP-AUY922 in PC12 cells.
    Zhang H; Ge F; Shui X; Xiang Y; Wang X; Liao C; Wang J
    Cell Stress Chaperones; 2021 May; 26(3):495-504. PubMed ID: 33629253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.
    Lee DH; Sung KS; Bartlett DL; Kwon YT; Lee YJ
    Cell Signal; 2015 Feb; 27(2):293-305. PubMed ID: 25446253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo.
    Lian J; Lin D; Xie X; Xu Y; Xu L; Meng L; Zhu Y
    Onco Targets Ther; 2017; 10():2219-2226. PubMed ID: 28458565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat Shock Protein 90 (Hsp90)-Inhibitor-Luminespib-Loaded-Protein-Based Nanoformulation for Cancer Therapy.
    K Rochani A; Balasubramanian S; Ravindran Girija A; Maekawa T; Kaushal G; Kumar DS
    Polymers (Basel); 2020 Aug; 12(8):. PubMed ID: 32796651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma.
    Okui T; Shimo T; Hassan NM; Fukazawa T; Kurio N; Takaoka M; Naomoto Y; Sasaki A
    Anticancer Res; 2011 Apr; 31(4):1197-204. PubMed ID: 21508365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage.
    Zaidi S; McLaughlin M; Bhide SA; Eccles SA; Workman P; Nutting CM; Huddart RA; Harrington KJ
    PLoS One; 2012; 7(4):e35436. PubMed ID: 22523597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.
    Walsby E; Pearce L; Burnett AK; Fegan C; Pepper C
    Oncotarget; 2012 May; 3(5):525-34. PubMed ID: 22619113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma.
    Augello G; Emma MR; Cusimano A; Azzolina A; Mongiovì S; Puleio R; Cassata G; Gulino A; Belmonte B; Gramignoli R; Strom SC; McCubrey JA; Montalto G; Cervello M
    Int J Cancer; 2019 May; 144(10):2613-2624. PubMed ID: 30488605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma.
    Seggewiss-Bernhardt R; Bargou RC; Goh YT; Stewart AK; Spencer A; Alegre A; Bladé J; Ottmann OG; Fernandez-Ibarra C; Lu H; Pain S; Akimov M; Iyer SP
    Cancer; 2015 Jul; 121(13):2185-92. PubMed ID: 25809731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
    Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
    Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.
    Eccles SA; Massey A; Raynaud FI; Sharp SY; Box G; Valenti M; Patterson L; de Haven Brandon A; Gowan S; Boxall F; Aherne W; Rowlands M; Hayes A; Martins V; Urban F; Boxall K; Prodromou C; Pearl L; James K; Matthews TP; Cheung KM; Kalusa A; Jones K; McDonald E; Barril X; Brough PA; Cansfield JE; Dymock B; Drysdale MJ; Finch H; Howes R; Hubbard RE; Surgenor A; Webb P; Wood M; Wright L; Workman P
    Cancer Res; 2008 Apr; 68(8):2850-60. PubMed ID: 18413753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSP90 inhibitor NVP-AUY922 induces cell apoptosis by disruption of the survivin in papillary thyroid carcinoma cells.
    Liu J; Sun W; Dong W; Wang Z; Qin Y; Zhang T; Zhang H
    Biochem Biophys Res Commun; 2017 May; 487(2):313-319. PubMed ID: 28412368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer.
    Bao XH; Takaoka M; Hao HF; Fukazawa T; Yamatsuji T; Sakurama K; Takigawa N; Nakajima M; Fujiwara T; Naomoto Y
    Oncol Rep; 2013 Jan; 29(1):45-50. PubMed ID: 23064324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
    Canonici A; Qadir Z; Conlon NT; Collins DM; O'Brien NA; Walsh N; Eustace AJ; O'Donovan N; Crown J
    Invest New Drugs; 2018 Aug; 36(4):581-589. PubMed ID: 29396630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complex Crystal Structure Determination of Hsp90
    He CX; Lv Y; Guo M; Zhou H; Qin W; Zhao D; Li HJ; Xing L; Zhou X; Li PQ; Yu F; He JH; Cao HL
    Front Oncol; 2022; 12():847556. PubMed ID: 35280745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922.
    Kühnel A; Schilling D; Combs SE; Haller B; Schwab M; Multhoff G
    Cells; 2019 Sep; 8(10):. PubMed ID: 31569342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer.
    Moser C; Lang SA; Hackl C; Wagner C; Scheiffert E; Schlitt HJ; Geissler EK; Stoeltzing O
    Anticancer Res; 2012 Jul; 32(7):2551-61. PubMed ID: 22753713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
    Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
    Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.